TECHWIRE 30
(CIX: WRAL30)  986.18  down arrow-3.82  (-0.39 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: Apple)  524.94  up arrow+5.93  (1.14 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: QUINTILES)  50.22  down arrow-0.38  (-0.75 %)  Updated: 06:40 PM EDT, Apr 17 2014
(OP: BASF SE)  110.32  up arrow+2.18  (2.02 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: BioCryst)  8.34    (0 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: BioDelivery)  7.42  up arrow+0.02  (0.27 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: CEMP)  9.67  up arrow+0.44  (4.77 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: Cisco Systems)  23.21  up arrow+0.18  (0.78 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  56.54  up arrow+0.16  (0.28 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: DARA)  2.55  up arrow+0.07  (2.82 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: EMC CORPORATION)  26.62  down arrow-0.08  (-0.3 %)  Updated: 06:40 PM EDT, Apr 17 2014
(NQ: Extreme Networks)  5.67  up arrow+0.05  (0.89 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: Facebook)  58.94  down arrow-0.78  (-1.31 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: GLAXOSMITHKLINE)  52.51  down arrow-0.31  (-0.59 %)  Updated: 06:40 PM EDT, Apr 17 2014
(NQ: GOOG)  536.10  down arrow-20.44  (-3.67 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: IBM)  190.01  down arrow-6.39  (-3.25 %)  Updated: 06:40 PM EDT, Apr 17 2014
(NY: LH)  101.31  down arrow-0.64  (-0.63 %)  Updated: 06:40 PM EDT, Apr 17 2014
(OP: Lenovo Group)  23.91  down arrow-0.23  (-0.96 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: MRK)  56.47  up arrow+0.21  (0.37 %)  Updated: 06:40 PM EDT, Apr 17 2014
(NQ: Microsoft Corp)  40.01  down arrow-0.39  (-0.97 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: NetApp)  35.87  down arrow-0.37  (-1.02 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: NOVARTIS AG)  84.67  up arrow+0.26  (0.31 %)  Updated: 06:40 PM EDT, Apr 17 2014
(OP: Novozymes A/S)  44.76  down arrow-0.15  (-0.33 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: PFIZER)  30.25  up arrow+0.16  (0.53 %)  Updated: 06:40 PM EDT, Apr 17 2014
(NQ: Pozen)  8.70  down arrow-0.03  (-0.34 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NY: RED HAT)  50.55  down arrow-0.07  (-0.14 %)  Updated: 06:40 PM EDT, Apr 17 2014
(NQ: BBRY)  7.15    (0 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: Salix)  101.06  up arrow+0.4  (0.4 %)  Updated: 08:10 PM EDT, Apr 17 2014
(NQ: SQI)  26.05  up arrow+0.05  (0.19 %)  Updated: 08:10 PM EDT, Apr 17 2014

Posts tagged “Quintiles”

October 31, 2013

Premium Lock Durham-based lab testing firm adding gear, people, space

BioAgilytix Labs, a fast-growing Durham laboratory providing contract testing for pharmaceutical, biotechnology and agricultural companies, has added new testing devices, more people, and is planning more space.

BioAgilytix BioAgilytix

Updated October 31, 2013

Premium Lock Quintiles' president resigning for 'personal' reasons; stock drops

John Ratliff John Ratliff, president and chief operating officer at Quintiles, has resigned, the company said early Thursday. Ratliff also is quitting as a member of the board.

Updated October 31, 2013

Premium Lock Quintiles stock tumbles 10% on news president is quitting, latest financials

Quintiles      The world's largest life science services firm says business is looking good, but Wall Street turned sour on its stock. In its latest earnings report early Thursday, Quintiles increased its earnings forecast and says new business commitments are up 29 percent. However, revenue was flat in the just-completed quarter.

Updated October 22, 2013

Premium Lock SAS ranks No. 2, Quintiles No. 18 in global Great Place to Work list

Several technology and life science firms with a major presence in North Carolina crack the top 25 in the annual World's Best Multinational Workplaces ranking. NetApp, Cisco, Google, Microsoft and Novartis all make the list.

World's Best Multinational Workplaces World's Best Multinational Workplaces

October 16, 2013

Premium Lock Quintiles closes Phase 1 drug testing group in India amid furor over trials

Given the mammoth size of India's population, drug testing firms such as Quintiles have targeted the country for trials. But Quintiles, the world's largest life science services firm, has shut down an early-stage test group. As to why, the Durham-based company doesn't have much to say. The Supreme Court of India is up in arms about testing.

A Quintiles facility in India A Quintiles facility in India

Updated October 8, 2013

Premium Lock Muscular Dystrophy Association picks Quintiles to build online neuromuscular disease registry

The MDA has struck an agreement with Quintiles, the world's largest life science services firm, to help the organization build a registry through which it hopes to advance the fight against muscular dystrophy and other diseases.

MDA MDA

September 24, 2013

Premium Lock Quintiles to test for cancer biomarkers to find best therapy for patients

Quintiles' headquarters   Quintiles (NYSE:Q) wants to find out if "pre-profiling" cancer patients to to get the genomic profile of tumors can help develop better, more targeted cancer therapies. Read more about a studt its doing with US Oncology Research.

September 17, 2013

Premium Lock It's official: Novella becomes Novella Clinical, a Quintiles company

Novella The marriage between Quintiles and Novella Clinical became official Monday when the deal in which Quintiles acquired its nearby rival closed.

August 28, 2013

Premium Lock Quintiles' big data project earns Computerworld honor - and cover

The world's largest life science services firm is crunching big data in thousands of ways with the goal of helping clients develop and deliver drugs more quickly. It's also one of 12 winners in Computerworld's first "Data+ Editor's Choice Awards." To sweeten the honor, Q's data team is featured on the magazine's cover. In an exclusive interview, WRALTechWire talks with Q's CIO about the project, the importance of big, clean data, and the award.

Quintiles' "cover guys" Quintiles' "cover guys"

August 28, 2013

Premium Lock Danish plant protection supply firm Cheminova expands RTP HQ

Crop science "This is part of our strategic investment plan for the business in North America," a company spokesman says. "Cheminova's business in the region grew 23 percent in 2012, and has also shown positive growth thus far in 2013."

Updated August 20, 2013

Premium Lock Quintiles, the Rodney Dangerfield of stocks, says 'Mad Money'

Quintiles CEO Tom Pike ventured into a Wall Street lion's den on Monday for a live interview with CNBC Mad Money host Jim Cramer. But rather than facing a mauling, Pike jousts in a friendly fashion with Cramer, who professes he likes the big "Q."

Tom Pike, left, banters with Jim Cramer Tom Pike, left, banters with Jim Cramer

August 15, 2013

Premium Lock Exclusive: Quintiles aims to grab oncology, medical device market share with Novella acquisition

Quintiles' acquisition of Novella Clinical gives the CRO industry's largest player a missing piece. Executives from both companies discuss the deal in an exclusive for WRALTechWire Insiders.

Paula Brown Stafford Paula Brown Stafford

Updated August 14, 2013

Premium Lock Quintiles buys local, says it is acquiring RTP-based Novella Clinical

Quintiles, the world's largest life science services firm, is growing even larger with the acquisition of a nearby competitor - Novella Clinical.

Novella Novella

August 13, 2013

Premium Lock Look for bullish Quintiles to make more acquisitions

Don't be surprised if the big "Q" gets even bigger - soon. Wall Street loves Quintiles after a strong earnings report, and its stock price remains more than 10 percent above its May IPO price. Now the Durham-based life science services firm is looking to enhance its growth with more deals.

Quintiles remains a Wall Street darling Quintiles remains a Wall Street darling

August 2, 2013

Premium Lock N.C. Biotech Center celebrates investment trifecta

The N.C. Biotech Center notes recent wins of three Triangle life science firms whose start included support from the Biotech Center

Heat Biologics IPO Heat Biologics IPO

August 1, 2013

Premium Lock Quintiles sets sights on addressing health industry needs of the future

Clinical trial services are Quintiles' bread and butter but the CRO industry's largest company sees other growth opportunities. Read more about Quintiles strategy.

Quintiles' headquarters   Quintiles' headquarters

August 1, 2013

Premium Lock Quintiles' $944M in 2Q revenue beats analyst estimates

Quintiles      The Durham CRO beat analyst estimates as net new business in the quarter grew 13 percent.

Updated July 26, 2013

Premium Lock Quintiles report: Health care collaborations lacking but partnerships coming

While pharmas, payers and providers have historically operated in silos, collaborations will be key for the future of health care, according to a new Quintiles report.

Quintiles "Collaboration Mandate" report Quintiles "Collaboration Mandate" report

July 1, 2013

Premium Lock Biotech IPO activity in 2Q is strongest since 2000, report says

Biotech IPOs represented 13 of the 21 venture-capital companies that went public in the second quarter. Get more more details of an analysis of second quarter IPOs.

Looking for cash? Looking for cash?

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll